Table 1

Characteristics of the study cohort with and without cardiovascular events of myocardial infarction, cardiac death, myocardial revascularisation and fatal or non-fatal stroke

CVE (n=96)No CVE (n=1326)p-Value
Age (years)58.54±10.6559.29±9.810.473
Body mass index (kg/m2)26.32±3.0726.22±3.210.790
Gender, men, % (n)70.8 (68)70.7 (938)0.984
Dyslipidaemia, % (n)88.5 (85)80.6 (1068)0.055
Hypertension, % (n)78.1 (75)72.9 (966)0.265
Current smoking, % (n)56.3 (54)51.2 (679)0.343
Duration of diabetes (years)10.24±6.668.64±6.500.151
Previous PCI, % (n)22.9 (22)24.0 (318)0.810
Previous CABG, % (n)1.0 (1)3.4 (45)0.208
Family history of CAD, % (n)17.7 (17)14.8 (195)0.224
Systolic blood pressure (mm Hg)124.94±14.64127.86±16.410.117
Diastolic blood pressure (mm Hg)74.93±9.1277.01±10.170.071
Left ventricle ejection fraction (%)60.4±10.263.7±8.0 <0.001
Total cholesterol (mmol/L)4.10±1.164.10±1.210.962
HDL-cholesterol (mmol/L)0.98±0.281.03±0.270.126
LDL-cholesterol (mmol/L)2.44±0.992.46±0.960.827
Triglycerides (mmol/L)1.79 (1.28, 2.53)1.56 (1.18, 2.21)0.054
Apo A1 (g/L)1.36±0.371.32±0.280.140
Apo B (g/L)0.99±0.340.94±0.330.113
HbA1c (%)7.89±1.547.50±1.33 0.007
Glucose (mmol/L)7.52±2.687.18±2.280.155
hs-CRP, mg/L1.83 (1.08, 4.47)1.54 (0.77, 3.23) 0.017
Uric acid (µmol/L)368.39±96.44340.26±93.36 0.005
eGFR (mL/min)82.03±24.5580.12±25.580.471
Fibrinogen (g/L)3.52±0.853.30±0.8 0.015
Medication
 Statin, % (n)69.8 (67)71.9 (953)0.707
 Aspirin, % (n)88.1 (84)86.7 (1149)0.794
 Beta-blocker, % (n)52.4 (50)48.2 (639)0.601
 Calcium channel blocker11.5 (11)20.7 (275)0.166
 ACEI/ARB30.0 (29)26.5 (351)0.521
 OADs, % (n)48.9 (47)54.3 (720)0.296
 Insulin, % (n)27.1 (26)25.8 (342)0.813
  OADs+insulin, % (n)13.5 (13)19.9 (264)0.215
  • Data are presented as mean ± SD, median (25th, 75th percentiles) or % (n).

  • p-values <0.05 in bold. 

  • ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; Apo, apolipoprotein; CVE, cardiovascular events; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin type A1C; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OADs, oral antidiabetic drugs.